Chronic Lymphocytic Leukemia

Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.

Clinicians weigh acalabrutinib vs zanubrutinib for relapsed CLL, focusing on adverse effects, trial data, and where pirtobrutinib fits next.

A new CIRI2-CLL model uses MRD and clinical data to better predict CLL survival after fixed-duration therapy, enabling personalized risk stratification.

Experts weigh continuous vs time‑limited CLL therapy, compare acalabrutinib and zanubrutinib, and debate when pirtobrutinib fits first line.

Liso-cel CAR T plus ibrutinib delivers deep remissions and high uMRD in relapsed CLL/SLL after multiple therapies, with manageable safety.

FDA approves a new rituximab biosimilar, boosting CD20 therapy options and market competition for B-cell cancers and autoimmune diseases in the US.

Phase 3 Asian trial shows acalabrutinib sharply improves progression-free survival vs chlorambucil-rituximab in untreated, medically unfit CLL patients with favorable safety.

Adding emavusertib to ibrutinib boosts response rates in relapsed/refractory PCNSL, including in BTKi-experienced patients, while safety monitoring addresses prior FDA hold concerns.

Monthly IVIG prophylaxis sharply lowers moderate infections in CLL with low IgG, suggesting better quality of life despite baseline Ig levels.

Real-world data link vitamin D supplements to longer watch-and-wait time before CLL treatment, prompting fresh debate on delaying progression.

Oncologists debate BTK inhibitor choices in relapsed CLL, exploring when MRD testing matters, toxicity management, and insurance hurdles.

Catherine Coombs, MD and oncologists weigh frontline CLL therapy choices, balancing BTK inhibitors vs fixed-duration venetoclax combinations as age, comorbidities, and new trial data guide decisions.

Early phase 2 results suggest 12-cycle pirtobrutinib–obinutuzumab yields high responses in untreated CLL with minimal cardiac effects.

Off-the-shelf CD19 CAR T azer-cel earns FDA Fast Track after early trials show striking responses in refractory CLL/SLL and marginal zone lymphoma.

FLAIR finds ibrutinib‑rituximab matches FCR quality of life in untreated CLL over 4 years, with distinct adverse‑effect tradeoffs.

New survey reveals CLL physicians and patients vary widely on post-BTK inhibitor tradeoffs, urging shared decisions beyond survival data.

Older men with CLL on BTK inhibitors face sharply higher atrial fibrillation risk, shaping drug choice and prompting stronger cardiovascular screening and monitoring.

Decade-long trial shows continuous ibrutinib delivers durable survival in high-risk or older CLL, with emerging uMRD and manageable cardiac risks.

UK trial data show TP53 and unmutated IGHV outperform copy-number complexity for CLL prognosis, guiding smarter molecular risk stratification.